US Broker Ratings

AptarGroup, Inc. (ATR) Stock Analysis: Attractive Growth Potential with 10.83% Upside

AptarGroup, Inc. (NYSE: ATR), a prominent player in the healthcare sector, continues to capture investor attention with its robust market presence and innovative solutions across the pharmaceutical, beauty, personal care,..

Teleflex Incorporated (TFX) Stock Analysis: An Investor’s Guide to Potential 33.95% Upside

Teleflex Incorporated (NYSE: TFX), a key player in the healthcare sector, specifically in the medical instruments and supplies industry, offers a diverse portfolio that spans vascular access, anesthesia, urology, and..

Ascendis Pharma A/S (ASND) Investor Outlook: Biotech Growth with a 31.85% Upside Potential

Ascendis Pharma A/S (NASDAQ: ASND), a biopharmaceutical company headquartered in Hellerup, Denmark, is making waves in the biotechnology sector with its innovative TransCon-based therapies aimed at addressing unmet medical needs...

Labcorp Holdings Inc. (LH) Stock Analysis: Unveiling 11% Upside Potential and Strong Buy Ratings

Labcorp Holdings Inc. (NYSE: LH), a leader in the healthcare diagnostics and research industry, presents a compelling opportunity for investors with its robust growth prospects and strong analyst ratings. Currently..

Integer Holdings Corporation (ITGR): Investor Outlook with a 24% Upside Potential

Integer Holdings Corporation (NYSE: ITGR), a key player in the healthcare sector specializing in medical devices, presents a compelling investment opportunity for individual investors. With a market capitalization of $4.19..

Waystar Holding Corp. (WAY) Stock Analysis: Exploring a 28.69% Potential Upside

Waystar Holding Corp. (WAY), a prominent player in the healthcare information services industry, stands out with its innovative cloud-based software solutions tailored for healthcare payments. With a market capitalization of..

Universal Health Services, Inc. (UHS) Stock Analysis: Exploring a 24.72% Potential Upside

Universal Health Services, Inc. (UHS), a prominent player in the healthcare sector, stands out in the medical care facilities industry with a market capitalization of $11.76 billion. Headquartered in King..

Inspire Medical Systems, Inc. (INSP) Stock Analysis: Evaluating a 63.94% Potential Upside in the Medical Device Sector

Inspire Medical Systems, Inc. (NYSE: INSP), a prominent player in the healthcare sector, is drawing significant attention from the investor community. With a market capitalization of $3.84 billion, the company..

Merit Medical Systems, Inc. (MMSI) Stock Analysis: Strong Buy Ratings and 16% Upside Potential

For investors seeking opportunities in the healthcare sector, Merit Medical Systems, Inc. (NASDAQ: MMSI) stands out with a compelling mix of strong analyst ratings and significant upside potential. As a..

Bausch + Lomb Corporation (BLCO) Stock Analysis: Insights on Healthcare Giant’s Moderate Growth and Investor Ratings

Bausch + Lomb Corporation (BLCO), a prominent player in the healthcare sector, is a company that many investors have their eyes on due to its substantial market presence and a..

Koninklijke Philips N.V. (PHG) Stock Analysis: Unpacking the 32.20% Potential Upside

Investors with an eye on the healthcare sector may find Koninklijke Philips N.V. (NYSE: PHG) a noteworthy contender, especially given its significant potential upside of 32.20%. As a leading player..

Rhythm Pharmaceuticals, Inc. (RYTM): Investor Outlook on a Biotechnology Standout with 12 Buy Ratings

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is carving a niche in the healthcare industry with its specialized focus on rare neuroendocrine diseases. As a commercial-stage biopharmaceutical entity, Rhythm Pharmaceuticals is making..

Genmab A/S (GMAB) Stock Analysis: 38.73% Potential Upside Fuels Investor Interest

Genmab A/S (NASDAQ: GMAB), a leading biotechnology company headquartered in Copenhagen, Denmark, is capturing investor attention with its promising outlook and a robust 38.73% potential upside. Operating in the dynamic..

ADMA Biologics Inc (ADMA) Stock Analysis: Unveiling a 59% Upside in the Biotech Sector

ADMA Biologics Inc (NASDAQ: ADMA), a prominent player in the biotechnology sector, has captured the attention of investors with a compelling potential upside of 59.32%. Specializing in plasma-derived biologics, ADMA..

TG Therapeutics, Inc. (TGTX): Investor Outlook with an 11.10% Upside Potential in Biotechnology

TG Therapeutics, Inc. (NASDAQ: TGTX), a prominent player in the biotechnology sector, continues to capture investor interest with its promising pipeline and strategic focus on B-cell mediated diseases. Headquartered in..

The Cooper Companies, Inc. (COO) Stock Analysis: Exploring a Potential 24% Upside

For investors seeking exposure to the healthcare sector, The Cooper Companies, Inc. (NYSE: COO) presents an intriguing opportunity. With a market cap of $14.92 billion, this healthcare titan operates within..

Glaukos Corporation (GKOS) Stock Analysis: Unveiling a 17.97% Potential Upside in the Medical Device Sector

Glaukos Corporation (NYSE: GKOS) is carving out a notable position within the healthcare sector, specifically in the medical devices industry. With a market capitalization of approximately $5.93 billion, this U.S.-based..

Cytokinetics, Incorporated (CYTK) Stock Analysis: Revenue Growth Soars Amid Promising Drug Pipeline

Cytokinetics, Incorporated (NASDAQ: CYTK), a notable player in the biotechnology sector, has captured investor attention with its robust 89.10% revenue growth and a promising pipeline of muscle-targeted therapies. The company,..

iRhythm Technologies, Inc. (IRTC) Stock Analysis: Navigating a 7.34% Potential Upside in the Digital Healthcare Arena

iRhythm Technologies, Inc. (NASDAQ: IRTC) is making waves in the digital healthcare sector, capturing investor interest with its innovative solutions in ambulatory cardiac monitoring. Headquartered in San Francisco, the company..

Blueprint Medicines Corporation (BPMC) Stock Analysis: A Biotech with Potential Amidst Challenging Metrics

Blueprint Medicines Corporation (NASDAQ: BPMC), a prominent player in the biotechnology sector, is capturing investor attention with its robust pipeline of precision therapies targeting genomically defined cancers and blood disorders...

US Broker Ratings

US Broker Ratings

FTSE 100

Funds